Summary
Understanding why we produce labels for neuropsychiatric conditions, such as Alzheimer’s disease (AD), and how we use those words to tell stories about our brain, as well as which groups control such diagnostic discourse, is important to a wise understanding of our cognitive abilities, their limitations, and even our very human nature. Here, we explore the history and current focus of a newly emerging field called neuroethics and explore its relationship (or lack thereof) to a newly created clinical syndrome called involuntary emotional expressive disorder (IEED). The main argument concerns the lack of neuroethical discussion of issues pertinent to social influences on disease and the construction of professional specialization. We are critical of the processes associated with the creation of both the field and the syndrome, and express concern about their eventual outcomes. The interaction of social, political, and business institutions, the inherent interests of the advancement of larger research projects (and the individuals that compose them), their potential for profit, and other incentives to enhance marketability and public attention toward certain research programs will be examined as we discuss the development of the field of neuroethics. Similarly, we argue that these social factors and forces are instrumental in the development of IEED as a recognizable category and condition. Our critique is guided by the hope that through such analyses we can improve our understanding of how we go about our academic activities in cognitive neuroscience and also improve our efforts to help people suffering from neuropsychiatric conditions, such as dementia.
Key Words: Neuroethics, IEED, diagnosis, neuropsychiatric conditions, bioethics, dementia
References
- 1.Caplan P, Gans M. Is there empirical justification for the category of ‘self defeating personality disorder’? Fern Psychol. 1991;1:263–278. doi: 10.1177/0959353591012006. [DOI] [Google Scholar]
- 2.American Psychiatric Association . Diagnostic and statistical manual of mental disorders (DSM-IV) 4th ed. Washington, DC: APA; 1994. [Google Scholar]
- 3.Waller S. The Wisconsin Card Sort: an empirical and philosophical analysis of presuppositions regarding flexibility of cognition. In: Figueroa R, Harding S, editors. Science and other cultures: issues in philosophies of science and technology. New York: Routledge; 2003. pp. 189–200. [Google Scholar]
- 4.Berrios GE. Alzheimer’s disease: a conceptual history. Int J Geriatr Psychiatry. 1990;5:355–365. doi: 10.1002/gps.930050603. [DOI] [Google Scholar]
- 5.Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde [In German] Allg Z Psychiatrie. 1907;64:146–148. [Google Scholar]
- 6.Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer’s 1907 paper, “Über eine eigenartige Erkankung der Hirnrinde.”. Clin Anat. 1995;8:429–431. doi: 10.1002/ca.980080612. [DOI] [PubMed] [Google Scholar]
- 7.Whitehouse PJ, Maurer K, Ballenger J, editors. Concepts of Alzheimer disease: biological, clinical, and cultural perspectives. Baltimore: Johns Hopkins Press; 2000. pp. 48–128. [Google Scholar]
- 8.Sachdev P. Is it time to retire the term “dementia?”. J Neuropsychiatry Clin Neurosci. 2000;12:276. doi: 10.1176/jnp.12.2.276. [DOI] [PubMed] [Google Scholar]
- 9.Whitehouse PJ. The end of Alzheimer disease. Alzheimer Dis Assoc Disord J. 2001;15:59–62. doi: 10.1097/00002093-200104000-00001. [DOI] [PubMed] [Google Scholar]
- 10.Gaines AD, Whitehouse PJ. Building a mystery: Alzheimer disease, mild cognitive impairment, and beyond. Philos Pychiatry Psychol. 2006;13:61–74. doi: 10.1353/ppp.2006.0037. [DOI] [Google Scholar]
- 11.Morris JC. Mild cognitive impairment is early-stage Alzheimer disease. Arch Neurol. 2006;63:15–16. doi: 10.1001/archneur.63.1.15. [DOI] [PubMed] [Google Scholar]
- 12.Whitehouse PJ, Juengst ET. Anti-aging medicine and mild cognitive impairment: practice and policy issues for geriatrics. J Am Geriatr Soc. 2005;53:1417–1422. doi: 10.1111/j.1532-5415.2005.53411.x. [DOI] [PubMed] [Google Scholar]
- 13.Darwin C. The expression of the emotions in man and animals. New York: Appleton; 1873. [Google Scholar]
- 14.Cummings JL, Arciniegas DB, Brooks BR, et al. Defining and diagnosing involuntary emotional expressive disorder. CNS Spectr. 2006;11:1–7. doi: 10.1017/s1092852900026614. [DOI] [PubMed] [Google Scholar]
- 15.Pollack AW. Marketing a disease, and also a drug to treat it. New York Times. May 9, 2005 [Available at http://www.nytimes.com].
- 16.Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurology. 2006;59:780–787. doi: 10.1002/ana.20828. [DOI] [PubMed] [Google Scholar]
- 17.Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004;63:1364–1370. doi: 10.1212/01.wnl.0000142042.50528.2f. [DOI] [PubMed] [Google Scholar]
- 18.Starkstem SE, Migliorelli R, Teson A, et al. Prevalence and clinical correlates of pathological affective display in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1995;59:55–60. doi: 10.1136/jnnp.59.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Arciniegas DB, Lauterbach EC, Anderson KE, et al. The differential diagnosis of pseudobulbar affect (PBA): distinguishing PBA among disorders of mood and affect. Proceedings of a roundtable meeting. CNS Spectr. 2005;10:1–14. doi: 10.1017/s1092852900026602. [DOI] [PubMed] [Google Scholar]
- 20.Avanir Pharmaceuticals. A national discussion about a debilitating condition. PBA Update 2005;2(February issue).
- 21.Potter VR. Bioethics: bridge to the future. Englewood Cliffs, NJ: Prentice-Hall; 1971. [Google Scholar]
- 22.Potter VR. Global bioethics: building on the Leopold legacy. East Lansing, MI: Michigan State University Press; 1988. [Google Scholar]
- 23.Whitehouse PJ. The rebirth of bioethics: extending the original formulations of Van Rensselaer Potter. American J Bioethics. 2003;3:W26–W31. doi: 10.1162/152651603322614751. [DOI] [PubMed] [Google Scholar]
- 24.Whitehouse P. Van Rensselaer Potter: an intellectual memoir. Camb Q Healthc Ethics. 2002;11:331–334. doi: 10.1017/S0963180102114058. [DOI] [PubMed] [Google Scholar]
- 25.Potter VR, Whitehouse PJ. Deep and global bioethics for a livable third millennium. Scientist. 1998;12:1–9. [Google Scholar]
- 26.Tong R. Teaching bioethics in the new millennium: holding theories accountable to actual practices and real people. J Med Philos. 2002;27:417–432. doi: 10.1076/jmep.27.4.417.8609. [DOI] [PubMed] [Google Scholar]
- 27.Murphy TF. Representation and balance on presidential commissions. Am Philos Assoc Newsl Philos Med [online serial] 2005; 04 [Available at: http://www.apa.udel.edu/apa/publications/newsletters/MedicineNL/v04n2.htm].
- 28.Illes J, Racine E. Imaging or imagining? A neuroethics challenge informed by genetics. Am J Bioethics. 2005;5:5–18. doi: 10.1080/15265160590923358. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Pierce J, Jameton A. The ethics of environmentally responsible health care. New York: Oxford University Press; 2001. [Google Scholar]
- 30.Baker R. A draft model aggregated code of ethics for bioethicists. Am J Bioeth. 2005;5:33–41. doi: 10.1080/15265160500245188. [DOI] [PubMed] [Google Scholar]
